Transparancy information: Devgen nv
(Thomson Reuters ONE) - Regulated informationZwijnaarde - 12 October, 2009 - In accordance with Article 15 §1first paragraph of the Act of May 2, 2007 on the disclosure of majorshareholdings in listed companies, Devgen nv hereby informs that inthe capital increase of 6 October 2009, 1,757,217 new shares werecreated, as the result of a private placement (1,753,339 shares) andthe exercise of warrants by employees of the company (3,878 shares).Information as of 6 October 2009: Basic data+-------------------------------------------------------------------+| Total share capital (EUR) | 1,473,668.99 ||----------------------------------------------------+--------------|| Total number of securities conferring voting | 19,648,951 || rights | ||----------------------------------------------------+--------------|| Total number of voting rights (the denominator): | 19,648,951 ||----------------------------------------------------+--------------|| Total number of securities conferring voting | N/A || rights by category: | ||----------------------------------------------------+--------------|| Total number of voting rights by category | N/A |+-------------------------------------------------------------------+Additional facts+-------------------------------------------------------------------+| Total number of convertible bonds conferring voting | none || rights | ||-------------------------------------------------------+-----------|| Total number of rights, materialized by certificates | 1,612,648 || or not, to subscribe to not yet issued securities | warrants || which confer voting rights | ||-------------------------------------------------------+-----------|| Total number of voting rights which result from the | 1,612,648 || exercise of these conversion or subscription rights | ||-------------------------------------------------------+-----------|| Total number of shares without voting rights | none |+-------------------------------------------------------------------+According to Article 14 of the Act of May 2, 2007 on the disclosureof major shareholdings in listed companies, Devgen nv hereby informsthat it received the following notification of shareholding:+-------------------------------------------------------------------+| | | Number of | Number of | % || | Denominator | voting rights | voting rights | voting || | | before the | after the | rights || | | transaction | transaction | ||---------+-------------+-----------------+---------------+---------|| Biovest | | | | || ComVa | 19.648.951 | 1.082.574 | 2.195.668 | 11,17 % || (Rudi | | | | || Mariën) | | | | |+-------------------------------------------------------------------+With the above mentioned capital increase Biovest Comva (Rudi Mariën)has obtained 429,594 new shares. Together with 683,500 existingshares acquired earlier, the reporting threshold of 10% was exceeded.About Devgen nvDevgen's mission is to enable farmers to sustainably grow more foodon less land, with less water, agrochemicals and labour.Devgen uses advanced biotechnology and molecular breeding technologyto make high yielding seeds and crop protection solutions with asuperior environmental profile.Devgen brings this technology to the market in the world's major foodand feed crops through two complementary strategies:- Licensing Devgen technology for use in corn, cotton and soy andselected other crops in exchange for R&D funding, and milestone androyalty payments.- Producing and selling its premium hybrid seeds in major fieldcrops such as rice, sunflower, sorghum, and pearl millet, in theIndian subcontinent and South-East Asia.In its Crop Protection unit, Devgen developed and has taken to marketa novel nematicide, an agro-chemical product that protects crops fromdamage by parasitic nematodes.Incorporated in 1997, Devgen has offices in Ghent (Belgium),Singapore, Hyderabad (India) and Delaware (US) and employs more than200 people.For more information please contact:Thierry Bogaert, Wim Goemaere, CFOCEOTel. +32 9 324 24 24 Tel. +32 9 324 24 24Thierry.Bogaert(at)devgen.com Wim.Goemaere(at)devgen.comOr visit: www.devgen.comThis press release may contain forward-looking statements containingthe words "anticipates", "expects" , "intends", "plans", "estimates","may" and "continues" as well as similar expressions. Such forwardlooking statements may involve known and unknown risks, uncertaintiesand other factors which might cause the actual results, performanceor achievements of Devgen to be materially different from any futureresults or achievements expressed or implied by such forward-lookingstatements. Factors that could cause or contribute to suchdifferences include, among others: agricultural risks anddifficulties, including weather factors, diseases and pests, thecosts and requirements of regulatory compliance and the speed withwhich approvals are received; public acceptance of biotechnologyproducts; political, economic and social developments in countrieswhere Devgen operates and other risks and factors detailed in thecompany's most recent annual report.These forward looking statements speak only as of the date ofpublication of this document. Devgen disclaims any obligation toupdate such forward looking statements in this document to reflectany change in its expectations, conditions or circumstances on whichsuch statement is based, unless required by law or regulation. Thisdocument does not constitute, or form part of, any offer orinvitation to sell or issue, or any solicitation of any offer, topurchase or subscribe for any securities issued by Devgen NV.http://hugin.info/135721/R/1347074/323772.pdfThis announcement was originally distributed by Hugin. The issuer is solely responsible for the content of this announcement.
Datum: 12.10.2009 - 22:30 Uhr
Sprache: Deutsch
News-ID 6820
Anzahl Zeichen: 0
contact information:
Town:
London
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 231 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Transparancy information: Devgen nv"
steht unter der journalistisch-redaktionellen Verantwortung von
Devgen (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
